Risk of fracture after androgen deprivation for prostate cancer.
Walsh
Patrick C
PC
D000726:Androgen Antagonists / Q000009:adverse effects* / Q000627:therapeutic use; D015519:Bone Density / Q000187:drug effects*; D004305:Dose-Response Relationship, Drug; D005598:Fractures, Spontaneous / Q000139:chemically induced* / Q000453:epidemiology; D007987:Gonadotropin-Releasing Hormone / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D008134:Long-Term Care; D008297:Male; D010024:Osteoporosis / Q000150:complications / Q000453:epidemiology; D011336:Probability; D016016:Proportional Hazards Models; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000453:epidemiology; D012189:Retrospective Studies
D000726:Androgen Antagonists; D007987:Gonadotropin-Releasing Hormone